Posts tagged personalized medicine
Roth starts Biocept at buy

Roth Capital Partners has initiated coverage on Biocept (NASDAQ:BIOC) with a “buy” rating and target price of $1.20. The stock closed at 63 cents on Monday.

“Through its proprietary technology platform capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and building commercial momentum, we believe Biocept is uniquely positioned as a leader in the emerging field of liquid biopsy and personalized medicine,” writes analyst Chris Lewis.

Read More
GeneNews closes note financing with Alumina

GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement.

Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 within the first 120 days. The 12% notes will have a term of one year.

Read More
GeneNews provides financing update

GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.

The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.

Read More
GeneNews and JTS Health in business acceleration pact

GeneNews (TSX:GEN) has entered into a collaboration agreement with JTS Health Partners of Atlanta to accelerate adoption of GeneNews’ menu of proprietary cancer tests, including its lead ColonSentry blood-test for assessing an individual’s current risk for colorectal cancer.

JTS, a leading national healthcare management consulting and professional services firm, will also work to maximize the efficiency and effectiveness of GeneNews’ revenue cycle management operations.

Read More
NovellusDx expands board, raises $10-million

Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board.

“The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong track records of success, is consistent with our effort to bring the best talent to NovellusDx and rapidly become the leader in personalized medicine,” CEO, Haim Gil-Ad, said in a statement.

Read More